Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.60 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.51 |
| ▸ | DRD2 | P14416 | 1/20 | 0.48 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.45 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | ADRA2A | P08913 | 4/20 | 0.42 |
| ▸ | ADRA2B | P18089 | 4/20 | 0.42 |
| ▸ | ADRA2C | P18825 | 4/20 | 0.42 |
| ▸ | HTR7 | P34969 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6326828 | 0.86 | SIGMAR1 (0.44) | SIGMAR1 | |
| SCHEMBL4520692 | 0.79 | SIGMAR1 (0.71) | SIGMAR1SLC18A3DRD2CARM1PRMT6 | |
| SCHEMBL4098226 | 0.78 | SIGMAR1 (0.60) | SIGMAR1SLC18A3DRD2CARM1PRMT6 | |
| SCHEMBL957621 | 0.75 | SIGMAR1 (1.00) | SIGMAR1SLC18A3DRD2CARM1PRMT6 | |
| Oxalic Acid SCHEMBL4533958 | 0.74 | SIGMAR1 (0.65) | SIGMAR1SLC18A3DRD2CARM1PRMT6 | |
| SCHEMBL14722001 | 0.74 | SIGMAR1 (0.40) | SIGMAR1 | |
| SCHEMBL954292 | 0.74 | SIGMAR1 (0.77) | SIGMAR1SLC18A3DRD2CARM1PRMT6 | |
| Oxalic Acid SCHEMBL4108518 | 0.74 | SIGMAR1 (0.55) | SIGMAR1SLC18A3DRD2CARM1PRMT6 | |
| SCHEMBL955900 | 0.72 | SIGMAR1 (0.77) | SIGMAR1SLC18A3DRD2CARM1PRMT6 | |
| Oxalic Acid SCHEMBL466885 | 0.71 | SIGMAR1 (0.90) | SIGMAR1SLC18A3DRD2CARM1PRMT6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2013028495-A1 | DIHYDROPYRIDOPHTHALAZINONE INHIBITORS OF POLY (ADP-RIBOSE) POLYMERASE (PARP) FOR THE TREATMENT OF MULTIPLE MYELOMA | BIOMARIN PHARMACEUTICAL INC. (US) | 2013-02-28 | — | — | WO | claimed |
| US-20170349554-A1 | COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASE | COGNITION THERAPEUTICS, INC. | 2017-12-07 | — | — | US | disclosed |
| US-20140378460-A1 | COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASE | COGNITION THERAPEUTICS, INC. (US) | 2014-12-25 | — | — | US | disclosed |
| EP-2747768-A2 | COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASE | Cognition Therapeutics, Inc. (US) | 2014-07-02 | — | — | EP | disclosed |
| WO-2013029060-A2 | COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASE | COGNITION THERAPEUTICS, INC. (US) | 2013-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140378460-A1 | COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASE | TMEM97, SLC18A2, SIGMAR1 | SIGMAR1 3/4885SLC18A3 9/4885DRD2 164/4885 |
| US-20170349554-A1 | COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASE | TMEM97, SLC18A2, SIGMAR1 | SIGMAR1 3/4885SLC18A3 9/4885DRD2 164/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.